ArticleBMC genomics2009
Anti-proliferative action of vitamin D in MCF7 is still active after siRNA-VDR knock-down.
Article in BMC genomics, 2009. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 18 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
18 citing papers in PubMed, 1 synthesis or guideline pooled it, 50 citations in OpenAlex.
- Obesity and cancer: the role of vitamin D.BMC cancer · 2014Pooled it
- Levels of Serum 25-Hydroxy Vitamin D in Benign and Malignant Breast Disease Patients: An Observational Study.Cureus · 2025Article
- Brk/PTK6 and Involucrin Expression May Predict Breast Cancer Cell Responses to Vitamin D3.International journal of molecular sciences · 2023Article
- The Four Horsemen of the Apocalypse: Cancer, Depression, Vitamin D Deficiency, and Obesity: An Observational Study.Disease markers · 2023Observational
- IL-6 Impairs the Activity of Vitamin D3 in the Regulation of Epithelial-Mesenchymal Transition in Triple Negative Breast Cancer.Asian Pacific journal of cancer prevention : APJCP · 2019Article
- A novel glutathione-triggered theranostic prodrug for anticancer and imaging in living cells.RSC advances · 2018Article
- Association of Vitamin D3 Level with Breast Cancer Risk and Prognosis in African-American and Hispanic Women.Cancers · 2017Article
- Regulation of calcitriol biosynthesis and activity: focus on gestational vitamin D deficiency and adverse pregnancy outcomes.Nutrients · 2015Review
- Vitamin D and the RNA transcriptome: more than mRNA regulation.Frontiers in physiology · 2014Review
- Article
- Chaperone properties of pdia3 participate in rapid membrane actions of 1α,25-dihydroxyvitamin d3.Molecular endocrinology (Baltimore, Md.) · 2013Article
- Plasma 25 hydroxyvitamin D level and blood gene expression profiles: a cross-sectional study of the Norwegian Women and Cancer Post-genome Cohort.European journal of clinical nutrition · 2013Article
- Cellular and molecular effects of vitamin D on carcinogenesis.Archives of biochemistry and biophysics · 2012Review
- Vitamin D and the mammary gland: a review on its role in normal development and breast cancer.Breast cancer research : BCR · 2012Review
- Article
- New vitamin D analogs as potential therapeutics in melanoma.Expert review of anticancer therapy · 2012Review
- Vitamin D and cancer: a review of molecular mechanisms.The Biochemical journal · 2012Review
- Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 4 institutions in 3 countries.
Funding
Abstract
backgroundThe active form of Vitamin D, 1,25-dihydroxyvitamin D3 (1,25D), has strong anti-proliferative effects, yet the molecular mechanisms underneath this effect remain unclear. In contrast, the molecular mechanism of 1,25D for the regulation of calcium homeostasis has principally been resolved, demonstrating a pivotal role for the vitamin D receptor (VDR).
resultsWe first addressed the question whether the anti-proliferative effects of 1,25D are influenced by VDR. Knockdown of VDR by siRNA did not affect the anti-proliferative effects of 1,25D in MCF7 breast cancer cells. This unanticipated finding led us to take an alternative approach using genome wide screens to study the molecular mechanisms of 1,25D in proliferation. For that purpose, four independently developed and stable 1,25D resistant MCF7 cell lines were analyzed. Array CGH identified a copy number alteration in a region of 13.5 Mb at chromosome 11q13.4-14.1 common to all four 1,25D resistant cell lines. Expression arrays revealed that no single gene was differentially expressed between the sensitive and resistant cells, but multiple membrane receptor signaling pathways were altered in the 1,25D resistant cell lines. Importantly, in the genome wide experiments neither VDR, CYP24A1 nor other known vitamin D signaling pathway genes were associated with 1,25D resistance.
conclusionIn conclusion, siRNA and genome wide studies both suggest that the anti-proliferative effects of 1,25D in MCF7 breast tumor cell lines do not rely on classical Vitamin D pathway per se.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.